Nabi vows to push ahead with vaccine work

Nabi Biopharmaceuticals says it has decided to push ahead with studies into a potential vaccine for staph bacteria after a late-stage trial failed a primary endpoint. Nabi formed an advisory panel to investigate the trial failure of StaphVAX. The panel concluded that the antibodies generated for the late-stage trial were inferior to the antibodies generated by vaccine lots in earlier studies.

"Today's announcement marks a new beginning for our Gram-positive program, which is much enhanced by the knowledge we've gained about the bacteria and immune response," said Nabi CEO Thomas H. McLain. "Moving forward, we have a clear development pathway on which to readily advance our vaccine and antibody products toward commercialization."

- here's the AP report for more

Suggested Articles

German scientists are targeting a protein-cutting enzyme that many viruses, including the coronavirus COVID-19, need to replicate.

The 100 largest companies trading on the London Stock Exchange have boosted the percentage of women on their boards, but has life sciences kept pace?

In this week's EuroBiotech Report, Bicycle lands Genentech collaboration, GSK inks COVOD-19 adjuvant deal and Grifols buys antibiotic assets.